Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP), executed a purchase of company common stock valued at $10,131 on June 12, 2026.
This transaction involved the acquisition of 7,350 shares of common stock at a price of $1.3784 per share. Following this purchase, Mr. Dow directly owns 24,131 shares of 60 Degrees Pharmaceuticals common stock.
The insider purchase comes as SXTP trades near its 52-week low of $1.22, with the stock down 85% over the past year. Analysts maintain a price target of $3.70, suggesting potential upside from current levels. According to InvestingPro, which offers comprehensive analysis including Fair Value estimates and financial health scores, the company shows a weak overall financial health rating.
In other recent news, 60 Degrees Pharmaceuticals Inc. has made several noteworthy announcements. The company has enrolled its first patient in a clinical trial aimed at evaluating tafenoquine for the treatment of babesiosis. This trial, which is randomized, double-blind, and placebo-controlled, is being conducted at five clinical sites in the northeastern United States and requires at least 24 patients for an interim analysis. Additionally, 60 Degrees Pharmaceuticals has appointed Eric Francois to its board of directors. Francois brings over 20 years of leadership experience in the healthcare and life sciences sectors.
Furthermore, the company has expanded the availability of its malaria prevention medication, ARAKODA (tafenoquine), through a partnership with the Runway Health telehealth platform. This collaboration enables U.S. travelers to obtain the medication online before traveling to malaria-endemic regions. In another development, 60 Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification to the U.S. Food and Drug Administration for Australian Chestnut Extract. The FDA has until May 25, 2026, to object to the notification, after which the company may market the dietary supplement if no objections are raised. These recent developments highlight the company’s ongoing efforts in both pharmaceutical and dietary supplement sectors.